机制和抗过敏的功效比较局部lodoxamide在春天的角膜结膜炎和色甘酸钠治疗。

文章的细节

引用

复制到剪贴板

Avunduk, Avunduk MC, Kapicioglu Z, Akyol N, Tavli L

机制和抗过敏的功效比较局部lodoxamide在春天的角膜结膜炎和色甘酸钠治疗。

眼科学。2000年7月,107 (7):1333 - 7。

PubMed ID

10890862 (在PubMed

]

文摘

目的:探讨局部lodoxamide和色甘酸钠治疗的作用机制在春天的角膜结膜炎(VKC)和比较这些药物的疗效。设计:Single-investigator、蒙面、随机临床试验。参与者:20男10女患者年龄在6 - 19年的,那些被诊断为活跃VKC,参加本研究。干预措施:患者随机分为两组(A和B组)。A组患者接受局部lodoxamide眼科解决方案(LOS) 0.1%;局部色甘酸钠眼科4%解决方案(方案)中规定的B组患者每日剂量的两滴四次。主要结果测量:眼睛症状严重程度得分和临床症状的病人进行评估的预处理和后处理。除了临床数据,结膜印迹细胞学标本取自患者治疗前后。印迹细胞学标本染色使用免疫组织化学方法检测CD4(+)的百分比,CD8 (+), CD45RA(+),和CD23(+)细胞。统计分析进行内部和之间的组织。结果:CD4(+)和CD23的百分比(+)细胞撕裂患者的样本组A和B在预处理阶段明显高于后处理阶段。 In the post-treatment stage, group A patients had significantly lower CD4(+) and CD23(+) cell values compared with group B patients. Patient symptom scores and clinical signs were at a significantly lower level after treatment with either LOS or CSO in both groups A and B compared with their pretreatment values. Moreover, group A patients had significantly lower symptom scores and clinical signs than group B patients in the post-treatment stage. CONCLUSIONS: Clinical superiority of LOS over CSO may be linked to its greater effect on the CD4(+) cells, because CD4(+) cells plays a pivotal role in the pathogenesis of VKC.

DrugBank数据引用了这篇文章

药物

Lodoxamide